About this Podcast:
In this episode, WCG’s President of Patient Advocacy, Steve Smith, interviews Dr. Jonathan Seltzer, MD, Chief Scientific Officer at WCG, expert on data safety monitoring boards, biomarkers, biostatistics, and clinical endpoints.
During their conversation, Steve and Dr. Seltzer discuss how biomarkers are appropriate for the use of trials, especially when clinical data is tough to get.
Part of this discussion turns to Duchenne’s Muscular Dystrophy (an inherited rare muscular disease) on how Patient Advocacy Groups are working with the FDA to define risk vs. benefit, and how promising a biomarker for this condition – as well as many other rare disorders – would be.
Don't trust your study to just anyone
WCG does DMCs right. Our experience, expertise, and personalized care helps sponsors organize, define, and gain insightful expertise to bridge from clinical trial to commercialization – and beyond. Experience the WCG difference starting with a free DMC services consultation.